Greenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPE

Rhea-AI Summary

Entera Bio (NASDAQ: ENTX) completed an oversubscribed $275 million private placement (PIPE), for which Greenberg Traurig advised the company. According to Entera Bio, the financing is expected to extend its cash runway into 2030 and fully support Phase 3 registrational studies of EB613, an oral PTH (1-34) tablet in development for osteoporosis.

According to data compiled by Arx Capital Markets, this is the largest publicly disclosed Israeli biotech PIPE on record and the ninth largest Israeli PIPE overall. The Greenberg Traurig deal team was led from Miami with support from the firm’s Tel Aviv office.

Positive

• $275 million oversubscribed PIPE financing completed
• Funding expected to extend cash runway into 2030
• Financing expected to fully support Phase 3 EB613 registrational studies
• Largest publicly disclosed Israeli biotech PIPE on record

Negative

• None.

News Explained

The $275 million offering equals 8009.7 days of Q1 cash use; reported cash equaled 120.5 days, with dilution unspecified.

Entera Bio describes an oversubscribed $275 million private placement financing, but the release gives no closing status or securities-issuance terms; its effect on existing ownership therefore cannot be established.

A private placement is a sale of securities to selected investors outside a public offering, with resale described as requiring a later registration statement that the issuer commonly commits to file.

On the same Q1 2026 operating-cash-use basis, the $275 million offering equals 8009.7 days of reported cash use, versus 120.5 days for cash and equivalents.

Sources and calculations

• Greenberg Traurig advises Entera Bio in record $275M Israeli biotech PIPE (2026-07-29)
• Private placement / PIPE definition (2026-07-17)
• Entera Bio first-quarter 2026 fundamentals (2026Q1)

• Offering gross vs quarterly operating cash outflow, in days of cash use $275,000,000 / ($3,090,000 / 90) = [object Object]
• Cash and equivalents vs quarterly operating cash outflow, in days of cash use $4,137,000 / ($3,090,000 / 90) = [object Object]

Market reaction after 275M PIPE financing: ENTX -7.98% in the Jul 29 session

-7.98%

19 alerts

-7.98% Session close to close

+3.8% Peak Tracked

-22.2% Trough Tracked

$211.00M Market Cap

0.3x Rel. Volume

In the Jul 29 session, ENTX declined 7.98%, reflecting a notable negative market reaction. Argus tracked a peak move of +3.8% during that session. Argus tracked a trough of -22.2% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -8.0% in the session following this news. -10% was Entera’s 24-hour reaction after i...

Analysis

The stock moved -8.0% in the session following this news. -10% was Entera’s 24-hour reaction after its May 8 quarterly-results announcement. A strong negative reaction here would extend recent divergence from favorable updates, with the active S-3 resale registration remaining a risk.

Key Figures

Private placement: $275 million Cash runway: 2030 Trial phase: Phase 3 +1 more

4 metrics

Private placement $275 million Oversubscribed financing

Cash runway 2030 Expected runway extension

Trial phase Phase 3 Registrational studies for EB613 in osteoporosis

Israeli PIPE ranking 9th largest Across all Israeli industries

Historical Context

5 past events · Latest: Jun 22 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 22	FDA protocol feedback	Positive	+22.3%	FDA accepted a single 750-patient Phase 3 trial protocol for EB613.
Jun 16	Preclinical data	Positive	-2.5%	Preclinical EB612 and EB618 data supported advancement toward clinical development.
Jun 15	Phase 1 data	Positive	-1.6%	Comparative Phase 1 EB613 data supported selection of the single-tablet candidate.
May 28	Conference presentation acceptance	Positive	+2.5%	Multiple oral peptide pipeline abstracts were accepted for ENDO 2026 presentations.
May 08	Quarterly results	Positive	-10.0%	Q1 results and program updates included funding and Phase 3 preparation.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and regulatory updates produced mixed price alignment, including declines after two favorable data announcements.

Key Terms

pipe, pth (1-34), registrational studies, private investment in public equity

4 terms

pipe financial

"its oversubscribed $275 million private placement financing"

A PIPE (private investment in public equity) is a deal in which institutional or accredited investors buy shares or convertible securities directly from a publicly traded company, usually at a discount to the market price. Companies use PIPEs to raise money faster than through a traditional public offering; for existing shareholders they matter because the newly issued shares add to the share count and can dilute ownership.

pth (1-34) medical

"the first oral PTH (1-34) peptide tablet"

pth (1-34) is a lab-made fragment of the human parathyroid hormone that acts like a short, active version of the natural hormone to stimulate bone growth and increase calcium levels. For investors, it matters because drugs based on this molecule are marketed as treatments for severe osteoporosis and related bone disorders, so clinical trial results, regulatory decisions, manufacturing capacity, and patent status can strongly affect a company’s revenue prospects and stock value.

registrational studies regulatory

"fully support Phase 3 registrational studies for EB613"

Clinical trials run specifically to provide the evidence regulators require for approval of a new drug, device, or treatment. They are the final, rigorous tests—like a product’s “final exam” or blueprint review—that determine whether a therapy can legally be marketed, so their outcomes directly affect a company’s ability to generate revenue, timelines to market and overall investment risk.

private investment in public equity financial

"private investment in public equity (PIPE) on record"

Private investment in public equity occurs when investors buy shares directly from a company that is publicly traded, often at an early stage or at a discount, instead of purchasing them on the open market. This allows investors to acquire a stake more quickly and with potentially better terms, which can influence the company's future growth and stability—making it an important option for those seeking to support or benefit from a company's development.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MIAMI, July 29, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its oversubscribed $275 million private placement financing.

The financing is expected to extend Entera Bio's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first oral PTH (1-34) peptide tablet in development for the treatment of osteoporosis, according to the company's press release.

This financing is the largest publicly disclosed Israeli biotech private investment in public equity (PIPE) on record and the ninth largest publicly disclosed Israeli PIPE transaction across all industries, according to data compiled by Arx Capital Markets, Entera Bio's investor relations firm.

The Greenberg Traurig team representing Entera Bio in this transaction was led by MiamiCorporate Practice Co-Chair Drew M. Altman and Miami Corporate Shareholder Sami B. Ghneim, with assistance from Miami Corporate Associate Angel A. Marcial and Tel-Aviv office Managing Shareholder Joey T. Shabot.

About Greenberg Traurig: Greenberg Traurig, LLP has approximately 3,200 lawyers across 51 locations in the United States, Europe, the Middle East, Latin America, and Asia. The firm's broad geographic and practice range enables the delivery of innovative and strategic legal services across borders and industries. Recognized as a 2025 BTI "Best of the Best Recommended Law Firm" by general counsel for trust and relationship management, Greenberg Traurig is consistently ranked among the top firms on the Am Law Global 100, NLJ 500, and Law360 400. Greenberg Traurig is also known for its philanthropic giving, culture, innovation, and pro bono work. Web: www.gtlaw.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/greenberg-traurig-advises-entera-bio-in-record-275m-israeli-biotech-pipe-302838075.html

SOURCE Greenberg Traurig, LLP

FAQ

What did Entera Bio (NASDAQ: ENTX) announce about its new $275 million PIPE financing?

Entera Bio announced an oversubscribed $275 million PIPE financing. According to Entera Bio, the proceeds are expected to extend its cash runway into 2030 and fully fund Phase 3 registrational studies of EB613, its oral PTH (1-34) osteoporosis candidate.

How will the $275 million PIPE impact Entera Bio’s cash runway and development plans for EB613 (ENTX)?

According to Entera Bio, the $275 million PIPE is expected to extend its cash runway into 2030. The company also expects the funding to fully support Phase 3 registrational studies of EB613, its oral osteoporosis therapy candidate, improving visibility on near- to mid-term development costs.

Why is Entera Bio’s $275 million PIPE considered a record transaction for Israeli biotech?

According to data cited by Entera Bio, the $275 million financing is the largest publicly disclosed Israeli biotech PIPE on record. It is also described as the ninth largest publicly disclosed Israeli PIPE transaction across all industries, highlighting its scale in the local capital market.

What is EB613 in Entera Bio’s (ENTX) pipeline and how is the PIPE financing related?

EB613 is described by Entera Bio as the first oral PTH (1-34) peptide tablet in development for osteoporosis. According to Entera Bio, the $275 million PIPE is expected to fully support Phase 3 registrational studies of EB613, covering key late-stage clinical development needs.

Who advised Entera Bio (ENTX) on its $275 million PIPE financing and what was Greenberg Traurig’s role?

Greenberg Traurig advised Entera Bio on the oversubscribed $275 million PIPE transaction. The firm reports the deal team was led by its Miami Corporate Practice Co-Chair and Corporate Shareholder, with additional support from a Miami associate and the Tel Aviv office’s Managing Shareholder.

How significant is the $275 million PIPE for Entera Bio’s Phase 3 plans in osteoporosis?

According to Entera Bio, the $275 million financing is expected to fully fund Phase 3 registrational studies of EB613 for osteoporosis. This suggests the company anticipates having sufficient capital for pivotal trials, assuming plans and cost expectations remain consistent with current projections.